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Abstract A series of 2-phenylethynyladenosine (PEAdo)
derivatives substituted in the N
6-a n d4 0-position was
synthesised and the new derivatives were tested at the four
human adenosine receptors stably transfected into Chinese
hamster ovary (CHO) cells, using radioligand binding
studies (A1,A 2A,A 3) or adenylyl cyclase activity assay
(A2B). Binding studies showed that the presence of a phenyl
ethynyl group in the 2 position of adenosine favoured the
interaction with A3 receptors, resulting in compounds
endowed with high affinity and selectivity for the A3
subtype. Additional substitution of the N
6- and 40-position
increases both A3 affinity and selectivity. The results
showed that the new compounds have a good affinity for
the A3 receptor and in particular, the N
6-methoxy-2-
phenylethynyl-50-N-methylcarboxamidoadenosine, with a
Ki at A3 of 1.9 nM and a selectivity A1/A3 and A2A/A3 of
4,800- and 8,600-fold, respectively. Therefore, it is one of
the most potent and selective agonists at the human A3
adenosine receptor subtype reported so far. Furthermore,
functional assays of inhibition of 10 μM forskolin-stimu-
lated cAMP production via the adenosine A3 receptor
revealed that the new trisubstituted adenosine derivatives
behave as full agonist of this receptor subtype. Docking
analysis of these compounds was performed at a homology
model of the human A3 receptor based on the bovine
rhodopsin crystal structure as template, and the results are
in accordance with the biological data.
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Introduction
Adenosine (Ado) is an endogenous modulator of a wide
range of biological functions in the nervous, cardiovascular,
renal and immune systems through interaction with four
receptor subtypes, termed A1,A 2A,A 2B and A3, which
belong to the family of G-protein-coupled receptors [1]. All
four Ado receptor subtypes are coupled to the enzyme
adenylylcyclase ineitheraninhibitory(A1 and A3 subtypes)
or stimulatory manner (A2A and A2B subtypes), and their
activation leads to a decrease or increase of cAMP levels,
respectively. In addition, all four subtypes may positively
couple to phospholipase C via different G protein subunits.
In particular, the A3 Ado receptor subtype exerts its action
through the stimulation of phospholipases C and D [2].
Although the physiological role of the A3 receptor subtype
is not clearly clarified, due to its recent characterisation and
the lack of really selective ligands for in vivo studies, it has
recently attracted significant interest as novel drug target. In
fact, A3 agonists may have potential as cerebroprotective
and cardioprotective agents and may also be potential drugs
for the treatment of asthma, as anti-inflammatory and
immunosuppressive agents and in cancer therapy as
cytostatics and chemoprotective compounds [3]. In many
papers, it has been reported that Ado derivatives bearing in
2 position (ar)alkenyl chains showed good affinity and high
degree of selectivity for the human A3 Ado receptor
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presence of a phenylethynyl group in the 2 position,
combined with small substituents, such as a methyl, in
N
6-position of Ado, favours interaction with A3 receptors,
leading to compounds with high affinity and selectivity for
the same subtype [7]. In addition, the substitution of the 40-
hydroxymethyl group of the sugar moiety with a methyl- or
ethylcarboxamido substituent enhanced A3 affinity [5, 8].
Starting from these observations and with the aim of
finding more potent and selective A3 Ado receptor agonists,
2-phenylethynyl Ado derivatives with a methoxy group in
the N
6-position were synthesised and tested at the four
human Ado receptors stably transfected into Chinese
hamster ovary (CHO) cells using radioligand binding
studies (A1,A 2A,A 3) or adenylyl cyclase activity assay
(A2B). The ability of the new compounds examined to
inhibit 10 μM forskolin-stimulated cAMP production via
the Ado A3 receptor was also studied. As genetic
information and molecular modelling of this receptor
subtype can facilitate the understanding and the rationalising
of the drug–receptor interaction, a molecular docking
analysis of these compounds was performed utilising a
homology model of human A3 receptor based on the bovine
rhodopsin crystal structure as template. The synthesis of
these new compounds will be reported elsewhere.
Materials and methods
Biological evaluation
Binding studies
Dissociation constants of unlabelled compounds (Ki values)
were determined in competition experiments in 96-well micro-
plates, as described recently [9]. For A2A and A3 Ado
receptors, the nonselective agonist [
3H]NECA (30 nM and
10 nM, respectively) was utilised as radioligand. The A1-
selective agonist 2-chloro-N
6-[
3H]cyclopentyladenosine ([
3H]
CCPA; 1 nM) was utilised for the characterisation of A1
receptor binding. Nonspecific binding was determined in the
presence of 100 μM R-PIA and 1 mM theophylline, respec-
tively. For details, see Klotz et al. [9]. All binding data were
calculated by nonlinear curve fitting with the programme
SCTFIT [10].
Adenylyl cyclase activity
Functional activity of the 2-phenylethynyladenosine (PEAdo)
derivatives was determined in adenylyl cyclase experiments.
Stimulation of adenylyl cyclase via A2B Ado receptors and
inhibition of forskolin-stimulated adenylyl cyclase via A3
receptors were measured as described earlier [9, 11].
Molecular modelling
Computational methodologies
All molecular modelling studies were carried out on a
2 CPU (PIV 2.0–3.0 GHZ) Linux PC. Homology model-
ling was done using Molecular Operating Environment
(MOE, version 2004.03) suite [12]. Docking studies were
done with Schrodinger Macromodel (ver. 8.0) [13, 14] and
Schrodinger Maestro interface.
Homology model of the human A3 receptor
A homology model of the human A3 receptor was built by
using the X-ray crystal structure of the resting state bovine
rhodopsin (pdb code: 1L9H [15]; available at the RCSB
Protein Data Bank) with a 2.6-Å resolution as structural
template.
In order to model the human A3 receptor, the amino acid
sequences of transmembrane (TM) helices of the human A3
receptor and bovine rhodopsin were aligned. In this phase,
some guanine nucleotide-binding protein-coupled receptor
(GPCR) highly conserved amino acid residues could work
as guide, including the DRY motif (D3.49, R3.50, Y3.51,
or D107, R108, Y109 respectively) and three Pro residues
(P4.60, P6.50, P7.50 or P145, P189, P245, respectively).
Boundaries that were identified from the X-ray crystal
structure of bovine rhodopsin were applied for the
corresponding sequences of the TM helices of the A3
receptor. Loop domains of the human A3 receptor were
constructed by the loop search method implemented in
MOE. Special care had to be given to the second
extracellular (E2) loop, which folds back over TM helices.
This loop limits the size of the active site, and their amino
acids could be involved in direct interactions with the
ligands. The presence of a conserved disulfide link between
cysteines in TM domain 3 (TM3) and E2 might be the
driving force to this particular fold of the E2 loop, so this
domain was modelled using a rhodopsin-like constrained
geometry around the E2TM3 disulfide bridge. Because of
the limited sequence similarity between the human A3
receptors and the template in the C-terminal domains, only
a short segment of this region was modelled. In particular,
the model ends with the Ser306 residue corresponding to
the Asp330 residue of the bovine rhodopsin template.
Once the heavy atoms were modelled, all hydrogen atoms
were added, and the protein coordinates were then
minimised with MOE using the AMBER94 [16] force
field. The minimisations were carried out by 1,000 steps of
steepest descent followed by conjugate gradient minimisa-
tion until the RMS gradient of the potential energy was less
than 0.05 kJ mol
−1 Å
−1.
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All agonist structures were manually docked into the
hypothetical TM binding site. This receptor region has
been established with the aid of published mutational data
[17–20]. The searching of favourable binding conforma-
tions was conducted by a Monte Carlo Conformational
Search protocol implemented in Schrodinger Macromodel.
The input structure consisted of the ligand and a shell of
receptor residues within the specified distance (6 Å) from
the ligand. A second external shell of all the residues within
a distance of 8 Å from the first shell was kept fixed. During
the Monte Carlo conformational searching, the input
structure was modified by random changes in user-specified
torsion angles (for all input structure atoms) and molecular
position (for the ligand). In this procedure, the ligand was
left free to be continuously reoriented within the hypothet-
ical binding site, and both ligand and internal shell residues
conformations could be explored and reciprocally relaxed.
The method consisted of 10,000 conformational search
steps with MMFF94s force field [21–27]. Only unique
structures within a 50 kJ mol
−1 energy window above the
found global minimum were saved. The resulting docked
complexes were subjected to MMFF94s energy minimisa-
tion with Schrodinger Macromodel until the RMS of the
conjugate gradient was less than 0.05 kJ mol
−1 Å
−1.
Results and discussion
Binding studies
The new compounds were evaluated at the human
recombinant Ado receptors stably transfected into CHO
cells utilising radioligand binding studies (A1,A 2A,A 3)o r
adenylyl cyclase activity assay (A2B). Receptor-binding
affinity was determined using [
3H]CCPA (2-chloro-N
6-
cyclopentyladenosine) as radioligand for A1 receptors
whereas [
3H]NECA (50-N-ethylcarboxamidoadenosine)
was used for the A2A and A3 subtypes. The relative
potencies of these compounds for the A2B subtype were
measured by evaluating the receptor-stimulated adenylyl
cyclase activity expressed as EC50. None of the tested
compounds revealed activity at A2B receptors at concentra-
tion up to 100 μM. The results are shown in Table 1.
PEAdo(1), 50-N-methylcarboxamidoadenosine
(PEMECA)(2), and 50-N-ethylcarboxamidoadenosine
(PENECA) (3) have been reported as reference compounds.
PEAdo (1) displayed a Ki at A3 of 16 nM and a selectivity
A1/A3 and A2A/A3 of 24- and 23-fold while replacement of
the hydroxymethyl group in 40-position of the sugar moiety
with a methyl or ethylcarboxamido substituent increased A3
affinity. In fact, the corresponding PEMECA(2)a n d
PENECA (3) derivatives showed increased A3 affinity and
selectivity compared with PEAdo with an unmodified
ribose (Table 1)[ 4–6, 28]. The introduction of the
methoxy group in N
6-position of 1 led to an enhancement
of A3 affinity of about four fold and a decrease of both A1
and A2A affinity of three and 12 fold, respectively, leading
again to a considerable improvement of A3 selectivity. The
N
6-methoxy-2-phenylethynylAdo (4) showed a Ki A3 =
3.8 nM and a selectivity A1/A3 and A2A/A3 of 320 and
1,100 fold, respectively [29]. Further substitution of the
40 position of the sugar moiety of 4 enhances the affinity
and/or selectivity of the corresponding compounds 5 and 6.
Thus, N
6-methoxy-2-phenylethynyl-50-N-ethylcarboxa-
midoadenosine (6) showed the same affinity as the 40-
hydroxymethylderivative 4 at A3 receptors (6;K i A3 =
3.5 nM vs. 4;K i A3 = 3.8 nM) combined with improved A3
selectivity (6; selectivity A1/A3 = 540 and A2A/A3 = 1,900
vs. 4; selectivity A1/A3 = 320 and A2A/A3 = 1,100) whereas
an increase of both affinity and selectivity was found for
Table 1 Biological data of new synthesised compounds (Ki nM).
Compound R1 R2 KiA1 KiA2A KiA3 A1/A3 A2A/A3
1 PEAdo [4–6]H C H 2OH 391 (284–556) 363 (285–462) 16 (13–19) 24 23
2 PEMECA H CONHMe 3,920 (2,390–6,430) 1,760 (1,360–2,280) 7.3 (4.2–13) 540 240
3 PENECA H CONHEt 560 (480–650) 620 (300–1,300) 6.2 (5.1–7.5) 90 100
4 OCH3 CH2OH 1,210 (893–1,630) 4,290 (3,170–5,810) 3.8 (2.6–5.5) 320 1,100
5 OCH3 CONHMe 9,140 (6,680–12,500) 16,300 (12,100–21,900) 1.9 (1.6–2.2) 4,800 8,600
6 OCH3 CONHEt 1,880 (1,330–2,660) 6,660 (3,730–11,900) 3.5 (2.9–4.2) 540 1,900
PEAdo 2-phenylethynyladenosine, PEMECA 50-N-methylcarboxamidoadenosine, PENECA 50-N-ethylcarboxamidoadenosine
N
N N
N
NH
O
OH HO
R2
R1
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6-methoxy-2phenylethynyl-50-N-
methylcarboxamidoadenosine (5), showing Ki A3 = 1.9 nM
and a selectivity A1/A3 and A2A/A3 of 4,800 and 8,600
fold, respectively, resulting in one of the most potent and
selective agonist at the human A3 Ado receptor subtype
reported so far. The ability of the new compounds
examined to inhibit 10 μM forskolin-stimulated cAMP
production via the Ado A3 receptor was also studied
(Table 2).
In particular, the functional assay based on the evalua-
tion of cyclic AMP levels in hA3 CHO cells shows that the
N
6-methoxy-PEAdo derivative 4 is a partial agonists com-
pared with the full agonist 2-chloro-N
6-(3-iodobenzyl)-50
methylcarboxamidoadenosine (Cl-IB-MECA) as a refer-
ence [30]. On the other hand, the two N
6-methoxy-
PEMECA (5) and N
6-methoxy-PENECA (6) derivatives
show an adenylyl cyclase inhibition comparable to Cl-IB-
MECA documenting that they are full A3 Ado agonists.
Molecular modelling
A molecular docking analysis of these compounds was
performed at a homology model of human A3 receptor built
using bovine rhodopsin crystal structure as template, with
the aim of obtaining a possible rationalisation of the
different binding affinities of the molecules for the human
A3 receptor. The compounds have the same core structure,
with different substituents in N
6-a n d4 0-position. In
particular, the different group bound to the 40 carbon of
the ribose moiety seems to influence both affinity and
selectivity of the compounds.
In Figure 1, the complexes of the hA3 receptor model
with three agonists are shown, PEAdo (1), N
6-methoxy-2-
phenylethynylAdo (4)a n dt h eN
6-methoxy-2-phenyle-
thynyl-50-N-methylcarboxamidoAdo (5). These compounds
share a common structure apart from the functionalisation
of the ribose group and the nitrogen in 6-position. The
docking conformations present the adenine scaffold plane
almost orthogonally with respect to the receptor axis, with
Table 2 Inhibition of adenylyl cyclase (AC) activity by new
compounds.
Compound % AC activity
a
4 81 ± 2.3
5 38 ± 3.2
6 35 ± 4.0
Cl-IB-MECA 40 ± 2.2
Shown is the percentage of activity remaining after agonist-mediated
inhibition of forskolin- stimulated cyclase activity (100%) ± standard
error of mean (SEM) (n =3 )
Cl-IB-MECA 2-chloro-N
6-(3-iodobenzyl)-50methylcarboxamidoade-
nosine
aAfter 10 μM forskolin stimulation
Figure 1 The complex of the hA3AR with three agonists, (A)
(PEAdo) 1; (B) N
6-methoxy-PEAdo 4; (C) N
6-methoxy- (PEMECA)
5 (c). The protein is in ribbons representation, and only the protein
residues are coloured according to atom type. H-bond interactions (as
indicated by the programme) are coloured in yellow
592 Purinergic Signalling (2006) 2: 589–594the 2-phenylethynyl group inserted in a space between
TM3 and TM6. These conformations are in accordance
with the already published docking conformation of PEAdo
[31]. The presence of a methoxy group in 6-position seems
to allow the ligand to interact with the receptor at two
points, S247 and N250; this could explain a better affinity
of N
6-methoxyAdo derivatives compared with the com-
pounds with an unmodified N
6-position. In addition, the 50-
N-methylcarboxamido group of the 5 derivative leads the
molecule to interact with the receptor in two points, L90
and S271, compared with the corresponding hydroxy-
methyl group in molecule 4, which can have only one H-
bond interaction with H272.
Conclusions
A series of PEAdo derivatives substituted in the N
6- and 40-
position was tested at the four human Ado receptors stably
transfected into CHO cells using radioligand binding
studies (A1,A 2A,A 3) or adenylyl cyclase activity assay
(A2B). The new compounds were also examined in their
ability to inhibit 10 μM forskolin-stimulated cAMP
production via the Ado A3 receptor. Binding studies
showed that the presence of a methoxy group in N
6 of
Ado derivatives favoured the interaction with A3 receptors,
obtaining compounds endowed with high affinity and
selectivity for the A3 subtype. Additional substitution with
an alkylcarboxamido group in 40-position increases both A3
affinity and selectivity. In particular, the N
6-methoxy-2-
phenylethynyl-50-N-methylcarboxamidoadenosine (5),
showed a Ki at A3 of 1.9 nM, a selectivity A1/A3 and
A2A/A3 of 4,800 and 8,600 fold, respectively, and also an
ability comparable to Cl-IB-MECA in inhibiting cAMP
production, resulting in one of the most potent and selective
agonist at the human A3 Ado receptor subtype reported so
far. Docking analysis of these compounds was performed at
a homology model of human A3 receptor built on the basis
of the bovine rhodopsin crystal structure as template, and
the results are in accordance with the biological data.
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